Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-Current Deffered Revenue: 2019-2025

Historic Non-Current Deffered Revenue for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $835,000.

  • 4D Molecular Therapeutics' Non-Current Deffered Revenue fell 34.77% to $835,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $835,000, marking a year-over-year decrease of 34.77%. This contributed to the annual value of $1.1 million for FY2024, which is 8.74% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Non-Current Deffered Revenue is $835,000, which was up 281.28% from $219,000 recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Non-Current Deffered Revenue registered a high of $11.7 million during Q1 2021, and its lowest value of $219,000 during Q2 2025.
  • Over the past 3 years, 4D Molecular Therapeutics' median Non-Current Deffered Revenue value was $972,000 (recorded in 2023), while the average stood at $933,091.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Non-Current Deffered Revenue plummeted by 84.94% in 2022 and then soared by 55.61% in 2024.
  • Over the past 5 years, 4D Molecular Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $2.5 million in 2021, then crashed by 56.80% to $1.1 million in 2022, then dropped by 9.67% to $972,000 in 2023, then climbed by 8.74% to $1.1 million in 2024, then tumbled by 34.77% to $835,000 in 2025.
  • Its Non-Current Deffered Revenue stands at $835,000 for Q3 2025, versus $219,000 for Q2 2025 and $434,000 for Q1 2025.